Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Disease Foundation Opens $500,000 in Grant Funding, Urges Scientists to Address Key Unmet Needs in Patient Community

New Awards Fund Translational Patient-Driven Research Projects

The Parkinson’s Disease Foundation® (PDF®) urges researchers to help solve, treat and end the unmet needs of the Parkinson’s community through its Translational Research Grants, an extension of the PDF Community Choice Research Awards Program. PDF’s investment of $500,000 will fund research projects to improve patient outcomes in four symptomatic areas identified by people living with the disease: cognitive change, dystonia A disorder in which muscles contract uncontrollably, causing abnormal movements and postures; can be very painful., fatigue and gastrointestinal dysfunction.

The PDF Community Choice Research Awards are the first grant awards in the Parkinson’s community to set research priorities based upon the insights of those living with the disease. Since the awards opened in 2013, the community has identified areas of need that, if addressed, could significantly improve the lives of people with Parkinson’s. In response, PDF has funded multidisciplinary working groups to identify strategies for solving, treating and ending each one. The new awards will advance that early work by jumpstarting translational research.

“These awards are an opportunity for scientists to make a direct impact on the lives of people with Parkinson’s,” said James Beck, Ph.D., Vice President, Scientific Affairs, PDF. “While PDF’s ultimate goal remains finding a cure, it is also vital that we help people live better today.”

PDF welcomes clinical, pre-clinical, or basic research proposals that will directly impact our understanding of four target symptomatic areas in Parkinson’s — cognitive change, dystonia, fatigue and gastrointestinal dysfunction — as outlined below. Funds are available for one year with levels of support varying based upon the project needs, and capped at $100,000 per award.

Targeted Reverse Translation Areas

  • Cognitive Change: Proposals should address gaps of knowledge, which include: the heterogeneity of cognitive change in Parkinson’s, risk factors for cognitive decline, biomarkers of cognitive change, the relationship of cognition to other non-motor symptoms, the role of nutrition or exercise in cognitive change and the relationship of patient-reported outcomes to clinical measures of functional impairment.
  • Dystonia: Proposals should address gaps in knowledge, which include: the role of dopaminergic and non-dopaminergic transmitters in dystonia, the identification of circuit-level or molecular changes that are key to driving dystonic movements in Parkinson’s and the identification of novel therapeutic targets for treatment. Also of interest are the development of models relevant to dystonia in Parkinson's and the characterization of a clinical study population best suited for studies (e.g., imaging).
  • Fatigue: Gaps in knowledge and possible research directions are summarized by PDF working groups in Friedman et al. 2016 (DOI: 10.1038/npjparkd.2015.25) and Kluger et al. 2016 (DOI: 10.1002/mds.26511). Proposals should seek to uncover the pathophysiologic basis of fatigue as well as further characterize phenomenological and epidemiological aspects of fatigue in Parkinson’s. Potential lines of research could examine biofluids for potential markers of fatigue or utilize fMRI or nuclear imaging to identify the neural basis to fatigue or the potential role of neuroinflammation.
  • Gastrointestinal Dysfunction: Proposals should address gaps in knowledge, which include: the need to accurately define Parkinson’s disease constipation and describe its phenomenology and the need to develop screening questionnaires to adequately collect relevant data. Investigations into the pathophysiology and natural history of constipation in Parkinson’s, using tools for motility monitoring or smartphone applications to facilitate frequent data collection, are also of interest.

Through the PDF Community Choice Research Awards, we asked, we listened and we engaged the community. Now, we invite scientists to help us find solutions,” said Daniel Novak, Ph.D., of Fort Worth, TX, Chair, PDF People with Parkinson’s Advisory Council. “It is encouraging to know that because of PDF’s vision, researchers will have the means to study some of the most debilitating, yet under-recognized aspects of Parkinson’s disease.”

Proposals that involve collaboration across disciplines and with the patient community are encouraged. Award decisions will be made in January 2017.

PDF will open its third survey for the Community Choice Research Awards to people with Parkinson’s and care partners in September 2016 to solicit additional feedback on unmet needs.

Thursday, July 21, 2016
In Memory of Robert Traurig
Wednesday, July 18, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member Robert (Bob) Traurig. From 2004 to 2015, he was a member of the Foundation’s board of directors. Bob is survived by his wife Jacqueline, his daughters Madeline Sackel and Wendy Traurig.

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.


mail icon

Subscribe to get the latest news on treatments, research and other updates.